Objective-Lp(a) [lipoprotein(a)] levels vary by race/ethnicity and were recently found to be associated with risk of heart failure (HF). We aimed to determine whether Lp(a)-related risk of HF is similar across different races and whether Lp(a) may further be related to HF with reduced ejection fraction or HF with preserved ejection fraction (HFpEF). Approach and Results-In 6809 participants of the MESA (Multi-Ethnic Study of Atherosclerosis), aged 45 to 84 years and free of cardiovascular disease, 308 incident HF events occurred during a median 13-year follow-up. Baseline Lp(a) concentrations were determined by immunoassay. Incident HF was adjudicated, distinguishing HF with reduced ejection fraction (ejection fraction, <45%) from HFpEF (ejection fraction, ≥45% 
H eart failure (HF) represents a major health-economic burden and, with their aging populations, Western nations are poised for a dramatic increase in rates of incident HF. [1] [2] [3] Considering the deleterious effects of HF on mortality, morbidity, and quality of life, 4,5 the identification and characterization of new HF risk factors is vital. Among these, Lp(a) [lipoprotein(a)] is a genetically determined low-density lipoprotein subclass that may represent one such target.
Lp(a) has been well characterized for its causal role in coronary heart disease and aortic valve stenosis 6, 7 but was only recently shown to be associated with greater risk of incident HF 8 and HF hospitalizations. 9 Potentially complicating this observation, Lp(a) distributions are known to vary widely based on race/ ethnicity. Indeed, race-based differences in circulating Lp(a) concentrations are well documented-with black individuals having, on average, 2-to 3-fold higher levels than whites 10, 11 and Hispanics. 12, 13 Additionally, racial/ethnic differences in Lp(a)-related risk of disease incidence have been suggested in recent studies of coronary heart disease 12 and aortic valve calcification (AVC) 11 -although counter evidence has also been reported. 10 It remains unknown whether Lp(a)-related risk of incident HF may differ across race/ethnicity, and no study has examined Lp(a) and risk of HF categorized by ejection fraction.
Overall, this study aimed to determine whether Lp(a)-related risk of incident HF is modified by race/ethnicity in MESA (Multi-Ethnic Study of Atherosclerosis) participants. Analyses were further conducted to determine whether observed relationships were mediated by ischemia-related events. Finally, previous studies 8, 9 have been unable to interrogate HF with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF), and these outcomes were examined here.
Materials and Methods
The authors declare that all supporting data are available within the article.
clinical cardiovascular disease, radiation-or chemotherapy-treated cancer, other serious major illness, or cognitive impairment in the judgment of the screening interviewer before baseline.
14 Between 2000 and 2002, 6814 men and women aged 45 to 84 years, of white, black, Hispanic, or Chinese racial/ethnic backgrounds, and without clinical evidence of overt cardiovascular disease were enrolled from 6 communities: Baltimore, MD; Chicago, IL; Forsyth County, NC; Los Angeles County, CA; New York, NY; and St. Paul, MN. The institutional review boards at all participating centers approved the study, and all participants signed informed consent. Additional study protocol information is available online at https://www.mesa-nhlbi.org.
Laboratory Measurements
Fasting blood was drawn, and EDTA-anticoagulant tubes were processed using a standardized protocol. 15 Samples were aliquoted then stored at −70°C until analyte measurements were conducted. Fasting triglyceride, total cholesterol, and HDL (high-density lipoprotein) cholesterol concentrations were measured as described previously. 16 Lp(a) mass concentrations served as the exposure variable and were measured at baseline in 6700 MESA specimens by Health Diagnostics Laboratory (Richmond, VA) using a latex-enhanced turbidimetric immunoassay (Denka Seiken, Tokyo, Japan) that controls for the heterogeneous sizes of apo(a) (apolipoprotein(a)). 17 Total imprecision was <5%.
Follow-Ups for Event Outcomes
Every 9 to 12 months, telephone interviewers called each participant to inquire about interim hospital admissions, cardiovascular outpatient diagnoses, and deaths. Inpatient and outpatient medical records and information were received in ≈98% and 95%, respectively. HF events were adjudicated by physicians based on medical records. We used ejection fraction reported in the hospital record to define HFrEF <45% versus HFpEF ≥45%. 18 Definite and probable myocardial infarction (MI) cases were identified based on combinations of symptoms, ECG, and cardiac biomarker levels. In most cases, definite or probable MI required either abnormal cardiac biomarkers (2× upper limits of normal) regardless of pain or ECG findings; evolving Q waves regardless of pain or biomarker findings; or a combination of chest pain, and ST-T evolution or new left bundle branch block, and biomarker levels 1 to 2× upper limits of normal.
Aortic Valve Calcification
AVC was identified at baseline by computed tomography. The imaging protocol has been described previously. 19 Briefly, computed tomographic imaging with either electron beam or multidetector scanners was used to detect AVC. Each participant was scanned twice, and the scans were interpreted at the core laboratory at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center by experienced readers who were blinded to the clinical information. Any calcified focus that extended to the aortic root was considered aortic valve calcium.
Statistical Analysis
Statistical analysis was conducted using STATA, version 15.0 (StataCorp, College Station, TX). Baseline characteristics are presented as means (SD) for continuous variables and frequencies (%) for categorical variables. Missing data were excluded when calculating frequencies. Tukey-Kramer was used to test the differences between groups. Cox regression determined associations between Lp(a) and incident HF across the 4 races/ethnicities. The proportional hazards assumption was determined using Schoenfeld residuals. To fully interrogate Lp(a) as a clinical cardiovascular risk marker, it was treated as both a log-transformed continuous variable and categorized variable using clinical cutoffs. US and European clinics use different Lp(a) clinical cutoff values (30 and 50 mg/dL, respectively), so both values were examined here. The regression model was adjusted for age, sex, body mass index, field center, education, smoking (pack-years), lipid-lowering medication, hypertension medication, systolic blood pressure, diastolic blood pressure, baseline glomerular filtration rate, diabetes mellitus, HDL cholesterol, total cholesterol, log-transformed triglycerides, and AVC at baseline (absent or present). Alcohol intake and baseline income were not related to the exposure or outcome variables and were excluded as covariates. Race/ethnicity was tested as a modifying variable. Unadjusted Nelson-Aalen hazard curves were generated to show differences in cumulative hazards of HF between individuals with Lp(a) above and below clinical cutoff values within each race/ethnicity. A secondary analysis assessed whether incident MI or ischemiarelated events mediate any observed relationships between Lp(a) and HF. Participants who suffered events were excluded as follows: model 1, incident MI; model 2, incident MI, coronary artery bypass grafting, or percutaneous transluminal coronary angioplasty. Associations between Lp(a) and HFrEF and HFpEF were tested using the above Cox regression model. P values <0.05 were deemed significant.
Results
In this sample of 6809 adults, there were 308 incident HF cases (3.9 per 1000 person-years). Table 1 shows demographic and clinical characteristics of study participants categorized by HF cases and noncases during the median 13-year follow-up period. Compared with noncases, individuals who experienced incident HF were more likely to be elderly (P<0.001), men (P<0.001), current or former smokers (P=0.03), diabetic (P<0.001), have a higher body mass index (P<0.001) and higher systolic and diastolic blood pressure (both P<0.001), taking hypertension medication (P<0.001), have lower levels of total cholesterol (P=0.02) and HDL cholesterol (P=0.005), have suffered an MI during the follow-up period, and have AVC at baseline (both P<0.001). Lp(a) levels did not differ between HF cases and noncases (P=0.29). The study sample was additionally stratified by Lp(a) categories and shown in Table 2 , and significant differences were observed in demographic, clinical, and lifestyle characteristics. Those in the top Lp(a) category (≥50 mg/dL) were more likely to be female, racially black, taking hypertension or lipid-lowering medication, have higher total and HDL cholesterol levels, have prevalent AVC at baseline and have suffered an MI event. No differences were observed in incident HF in this nonracially stratified sample. Lp(a) distributions for each race/ethnicity are presented in Figure I in the online-only Data Supplement.
Cox regression analysis estimated Lp(a)-related risk of HF with adjustments for age, sex, field center, education, body mass index, smoking (pack-years), systolic blood pressure, diastolic blood pressure, hypertension medication use, baseline glomerular filtration rate, HDL cholesterol, total cholesterol, log triglycerides, lipid-lowering medication use, diabetes mellitus, and prevalent AVC (Table 3) . Lp(a) was found to be related to greater risk of HF during the median 13-year follow-up period in whites alone. Per log unit of Lp(a) was associated with 20% greater risk of A secondary analysis evaluated whether Lp(a)-related risk of HF was mediated through ischemia-related events in white study participants, presented in Table 4 . In model 1, individuals who suffered an MI event were excluded from the analysis (n=124). Per log unit of Lp(a) was associated with 37% greater risk of HF (P=0.002). Those with Lp(a) levels ≥30 and ≥50 mg/dL showed 97% (P=0.006) and 143% (P=0.001) greater risks of HF, respectively. In model 2, in addition to excluding those who suffered an MI, we further excluded participants who underwent coronary artery bypass grafting (n=69) or percutaneous transluminal coronary angioplasty (n=137). Per log unit of Lp(a) was associated with 29% greater risk of HF (P=0.02). Those with Lp(a) levels ≥30 mg/ dL did not show a significantly greater risk of HF than those below this level (P=0.14), whereas individuals with Lp(a) levels ≥50 mg/dL showed an approximate 2-fold greater risk of HF than those <50 mg/dL (P=0.03).
In Table 5 , HF outcomes were subdivided into HFrEF (<45%) and HFpEF (≥45%) cases, and Cox regression estimated hazard ratios in white participants. Per log unit Lp(a) was associated with a 48% greater risk of HFpEF (P=0.002). Those with Lp(a) levels ≥30 and ≥50 mg/dL showed approximate 2-fold (P=0.02) and 2.5-fold (P=0.004) greater risks of HFpEF than those below these levels, respectively. No significant relations were found between Lp(a) and risk of HFrEF. No significant risk associations were observed between Lp(a) and HFpEF or HFrEF within any of the other racial/ethnic groups (data not shown).
Discussion
In this multiethnic cohort, Lp(a) was found to be a significant risk factor for incident HF in white individuals alone. Race interactions suggested that Lp(a)-related risk of HF is modified by race/ethnicity. Lp(a)-related risk of HF was found to be independent of the known influence of Lp(a) on aortic valve disease and may also be independent of ischemia-related events. Further categorizing HF by ejection fraction revealed that higher Lp(a) levels were related to significantly greater risk of HFpEF in white participants.
To date, 2 previous cohort studies have examined Lp(a) and HF-related outcomes. Combining 2 Danish Copenhagenbased cohorts, Kamstrup and Nordestgaard (2016) showed that increasing Lp(a) levels were associated with greater risk of incident HF (P for trend, <0.001). 8 Excluding individuals with previous MI or aortic valve stenosis showed that they mediated approximately two-thirds of HF risk, yet the association between Lp(a) and HF remained significant. Similarly, in ARIC (Atherosclerosis Risk in Communities) participants, Agarwala et al 9 showed that individuals in the top quintile (23.1-108.2 mg/dL) of Lp(a) were at a greater risk of HF hospitalization compared with those in the referent quintile (0.02-2.4 mg/dL); however, on excluding those with prevalent or incident MI, the relationship was rendered nonsignificant.
In addition, and in stark contrast to our findings, ARIC investigators found no evidence of a race interaction with Lp(a) and HF hospitalization (P for race interaction, 0.65).
Several factors may have contributed to the above differential findings. First, the HF outcome variables were distinct-HF hospitalizations were examined in ARIC in contrast to HF incidence in MESA and in the Copenhagen cohort study. In terms of the exposure variable, Lp(a) was examined using different approaches. The Danish cohort investigators examined Lp(a) based on percentile categories (ie 1-33, 34-66, 67-90, 91-99, and >99). Because MESA did not have the statistical power to mimic this approach, Lp(a) was examined as both a continuous variable and by clinical cutoffs while stratifying by race/ethnicity. In contrast, the ARIC study combined black and white individuals and categorized Lp(a) by quintiles. This approach may have biased the results in the ARIC sample considering that there are substantial differences in Lp(a) distributions between black and white groups, which results in unequal representations of black and white individuals across quintiles. Furthermore, we observed no relation between Lp(a) and HF risk in black MESA participants; therefore, combining Cox proportional hazards ratios and 95% CIs are shown (P values where significant). Lp(a) was modeled as a continuous variable (per log unit) and by clinical cutoff values, 30 and 50 mg/dL. Covariate adjustments were made for age, sex, field center, education, BMI, smoking (pack-years), systolic blood pressure, diastolic blood pressure, hypertension medication use, baseline glomerular filtration rate, HDL-C, total cholesterol, log triglycerides, lipid-lowering medication use, diabetes mellitus, and prevalent AVC. Interactions with race/ethnicity were tested both across race and between individual races/ethnicities. AVC indicates aortic valve calcification; BMI, body mass index; HDL-C, high density lipoprotein-cholesterol; and Lp(a), lipoprotein(a).
*Indicates significance, P<0.05 †Indicates that the association was significantly different than that in white participants (P for interactions, <0.05). these 2 race groups in ARIC may have weakened Lp(a)-related HF risk in upper quintiles. Ultimately, it may be speculated that the findings in ARIC may have been more consistent with MESA and the Copenhagen cohorts study had the sample been stratified by race and Lp(a) analyzed by a clinical cutoff(s). Supporting this assertion, we applied the statistical approach of the ARIC study to black and white MESA participants, and no significant relationship was observed between Lp(a) and incident HF across quintiles (data not shown). The mechanism through which Lp(a) may influence HF remains unknown, but it was hypothesized that ischemia-related events, such as MI, would have a mediating influence on Lp(a)-related risk of HF. In a secondary analysis, we used an approach similar to that of previous investigators 8, 9 and excluded individuals who suffered an MI (Table 3, model 1) . In a subsequent model (Table 3 , model 2), we next excluded those who suffered an MI, underwent coronary artery bypass grafting or percutaneous transluminal coronary angioplasty. With one exception, Lp(a)-related risk of HF was stronger in terms of the magnitudes of associations for Lp(a) exposure variables. While these findings suggest that associations are independent of MI or ischemia-related events in this sample, it must be acknowledged that statistical power was reduced in these analyses. Additional studies are warranted to determine whether Lp(a) is a causal risk factor for HF as found for coronary heart disease and aortic valve stenosis and, if the case, to identify the pathways that are promoting disease development.
Future Research
Despite the thousands of studies conducted on Lp(a) since its identification in 1963, 20, 21 its physiological and pathophysiological mechanisms remain ill defined, and clinical cutoff values have not been standardized. 22 The current finding that Lp(a)-related risk of HF varies across race/ethnicity suggests that the pathogenicity of the Lp(a) particle may be race dependent or is otherwise heterogeneous across populations. Given the possibility of race-based differences in Lp(a)-related risk, further biomolecular-, genetic-, and cohort-based research is warranted. Specifically, future studies that focus on identifying interrace differences in the LPA gene (in addition to the well-described KIV type II domain 23 ) and in Lp(a) particle components and structure may reveal functions and pathophysiological mechanisms of Lp(a) that remain uncharacterized. The present findings also support the need for standardized, race-dependent clinical cutoffs to discriminate disease risk.
Strengths and Limitations
This study represents the largest evaluation of Lp(a) and incident HF categorized by ejection fraction and shows that Lp(a)-related risk of HF is modified by race/ethnicity. The prospective study design and extended follow-up period allowed for the examination of temporality of associations between Lp(a) and HF outcomes. In terms of limitations, the definition of AVC was restricted to the presence of AVC at baseline, and we could not evaluate the potential influence of subsequent AVC development on HF incidence. It must also be acknowledged that statistical power may have been limited in analyses of HF categorized by ejection fractions excluding individuals with ischemia-related events; these findings should be interpreted with caution until replicated in other cohorts. MESA is a US-based cohort, and the present results may not be generalizable to other populations. Finally, multiple demographic and clinical adjustments were made within the statistical model, but the possibility of residual confounding cannot be excluded.
Conclusions
In a multiethnic cohort, Lp(a) was found to be an independent risk factor for HF and HFpEF in white individuals alone. Confirmation in other cohorts is warranted, but a Cox proportional hazards ratios and 95% CIs are shown (P values where significant). Lp(a) was modeled as a continuous variable (per log unit) and by clinical cutoff values, 30 and 50 mg/dL. Covariate adjustments were made for age, sex, field center, education, BMI, smoking (pack-years), systolic blood pressure, diastolic blood pressure, hypertension medication use, lipid-lowering medication use, baseline glomerular filtration rate, HDL-C, total cholesterol, log triglycerides, diabetes mellitus, and prevalent AVC. AVC indicates aortic valve calcification; BMI, body mass index; EF, ejection fraction; HDL-C, high density lipoprotein-cholesterol; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; and Lp(a), lipoprotein(a).
*HFpEF: EF, ≥45%. †Individuals with missing covariates or EF data were excluded from the analysis. ‡Indicates significance, P<0.05.
